Radiosynthesis, biodistribution and imaging of [11C]YM155, a novel survivin suppressant, in a human prostate tumor-xenograft mouse model

Nuclear Medicine and Biology

Volumn 40, Issue 2, 2013, Pages 221-226

  Murakami, Yoshihiro ^a   Matsuya, Takahiro ^a   Kita, Aya ^a   Yamanaka, Kentaro ^a   Noda, Akihiro ^a   Mitsuoka, Keisuke ^a   Nakahara, Takahito ^a   Miyoshi, Sosuke ^a   Nishimura, Shintaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

11C labeling; Antitumor drug; Chemotherapy; Positron emission tomography; Sepantronium bromide; YM155

Indexed keywords

RADIOPHARMACEUTICAL AGENT; SEPANTRONIUM BROMIDE; SEPANTRONIUM BROMIDE C 11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER TISSUE; CECUM; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG PURITY; DRUG SYNTHESIS; DRUG TUMOR LEVEL; KIDNEY; LIVER; MALE; METHYLATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; RADIOACTIVITY; RADIOCHEMISTRY; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CARBON RADIOISOTOPES; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMIDAZOLES; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICE; NAPHTHOQUINONES; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOCHEMISTRY; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

EID: 84872903578     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.10.002     Document Type: Article

References (33)

1. Wahl R.L., Jacene H., Kasamon Y., Lodge M.A. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(Suppl. 1):122S-150S.
2. Anderson H., Singh N., Miles K. Tumour response evaluation with fluorodeoxyglucose positron emission tomography: research technique or clinical tool?. Cancer Imaging 2010, 10(Spec no A):S68-S72.
3. Been L.B., Suurmeijer A.J., Cobben D.C., Jager P.L., Hoekstra H.J., Elsinga P.H. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004, 31:1659-1672.
4. Bading J.R., Shields A.F. Imaging of cell proliferation: status and prospects. J Nucl Med 2008, 49(Suppl. 2):64S-80S.
5. Visser G.W., van der Wilt C.L., Wedzinga R., Peters G.J., Herscheid J.D. 18F-radiopharmacokinetics of [18F]-5-fluorouracil in a mouse bearing two colon tumors with a different 5-fluorouracil sensitivity: a study for a correlation with oncological results. Nucl Med Biol 1996, 23:333-342.
6. Leung K. [18F]-N-(2-Chloro-6-methylphenyl)-2-(6-(4-(2-fluoroethyl)piperazin-1-yl)-2 -methylpyrimidin-4-ylamino)thiazole-5-carboxamide. Molecular Imaging and Contrast Agent Database 2004.
7. Hsueh W.A., Kesner A.L., Gangloff A., Pegram M.D., Beryt M., Czernin J., et al. Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET. J Nucl Med 2006, 47:1995-1999.
8. Gangloff A., Hsueh W.A., Kesner A.L., Kiesewetter D.O., Pio B.S., Pegram M.D., et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with (18)F-fluoropaclitaxel. J Nucl Med 2005, 46:1866-1871.
9. Chopra A. [N-11C-methyl]-[4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-py ridyl)-2-pyrimidinyl]amino]phenyl]benzamide. Molecular Imaging and Contrast Agent Database 2004.
10. Zhang M.R., Kumata K., Hatori A., Takai N., Toyohara J., Yamasaki T., et al. [11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma. Mol Imaging Biol 2010, 12:181-191.
11. Monazzam A., Josephsson R., Blomqvist C., Carlsson J., Langstrom B., Bergstrom M. Application of the multicellular tumour spheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res 2007, 9:R45.
12. Veach D.R., Namavari M., Pillarsetty N., Santos E.B., Beresten-Kochetkov T., Lambek C., et al. Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 2007, 50:5853-5857.
13. Memon A.A., Jakobsen S., Dagnaes-Hansen F., Sorensen B.S., Keiding S., Nexo E. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. Cancer Res 2009, 69:873-878.
14. Achmad A., Hanaoka H., Yoshioka H., Yamamoto S., Tominaga H., Araki T., et al. Predicting cetuximab accumulation in KRAS wild-type and KRAS mutant colorectal cancer using 64Cu-labeled cetuximab positron emission tomography. Cancer Sci 2012, 103:600-605.
15. Nagengast W.B., de Korte M.A., Oude Munnink T.H., Timmer-Bosscha H., den Dunnen W.F., Hollema H., et al. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010, 51:761-767.
16. McLarty K., Cornelissen B., Cai Z., Scollard D.A., Costantini D.L., Done S.J., et al. Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts. J Nucl Med 2009, 50:1340-1348.
17. Dijkers E.C., Oude Munnink T.H., Kosterink J.G., Brouwers A.H., Jager P.L., de Jong J.R., et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther 2010, 87:586-592.
18. Kesner A.L., Hsueh W.A., Htet N.L., Pio B.S., Czernin J., Pegram M.D., et al. Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts. J Nucl Med 2007, 48:2021-2027.
19. Nakahara T., Takeuchi M., Kinoyama I., Minematsu T., Shirasuna K., Matsuhisa A., et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007, 67:8014-8021.
20. Kita A., Nakahara T., Yamanaka K., Nakano K., Nakata M., Mori M., et al. Antitumor effects of YM155, a novel survivin suppressant, against human aggressive non-Hodgkin lymphoma. Leuk Res 2011, 35:787-792.
21. Satoh T., Okamoto I., Miyazaki M., Morinaga R., Tsuya A., Hasegawa Y., et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009, 15:3872-3880.
22. Giaccone G., Zatloukal P., Roubec J., Floor K., Musil J., Kuta M., et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009, 27:4481-4486.
23. Iwasa T., Okamoto I., Suzuki M., Nakahara T., Yamanaka K., Hatashita E., et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008, 14:6496-6504.
24. Iwasa T., Okamoto I., Takezawa K., Yamanaka K., Nakahara T., Kita A., et al. Marked anti-tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer 2010, 103:36-42.
25. Nakahara T., Yamanaka K., Hatakeyama S., Kita A., Takeuchi M., Kinoyama I., et al. YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model. Anticancer Drugs 2011, 22:454-462.
26. Yamanaka K., Nakahara T., Yamauchi T., Kita A., Takeuchi M., Kiyonaga F., et al. Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models. Clin Cancer Res 2011, 17:5423-5431.
27. Kin-ya S., Katsuhiro S., Eiji N., Tsuyoshi M., Tadashi H., Harumitsu I., et al. Metabolism of YM155 monobromide, a novel survivin suppressant: in vitro species comparison and identification of metabolites in rats. Drug Metab Rev 2007, 39:253-254.
28. Matsuhisa A, Kinoyama, I., Toyoshima, A., Nakahara, T., Takeuchi, M., Okada, M. Patent No: US6,734,203 B2, (2004).
29. Prescott B. Potential antimalarial agents. Derivatives of 2-chloro-1,4-naphthoquinone. J Med Chem 1969, 12:181-182.
30. Mitsuoka K., Miyoshi S., Kato Y., Murakami Y., Utsumi R., Kubo Y., et al. Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. J Nucl Med 2008, 49:615-622.
31. Tsukada H., Sato K., Fukumoto D., Nishiyama S., Harada N., Kakiuchi T. Evaluation of D-isomers of O-11C-methyl tyrosine and O-18F-fluoromethyl tyrosine as tumor-imaging agents in tumor-bearing mice: comparison with L- and D-11C-methionine. J Nucl Med 2006, 47:679-688.
32. Zhong-Lin L., Xue-Rui W., Bian-Bian L., Rui-Yao W. Palladacycles with C, N-bidentate and N, C, N'-tridentate ligands: Structures, spectral study and catalytic methanolysis of P=S pesticides. J Organomet Chem 2010, 695:2191-2200.
33. Minematsu T., Iwai M., Sugimoto K., Shirai N., Nakahara T., Usui T., et al. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1 H-naphtho[2,3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos 2009, 37:619-628.